<DOC>
	<DOCNO>NCT00800748</DOCNO>
	<brief_summary>This 3 arm study assess safety efficacy combination treatment peginterferon alfa-2a + ribavirin participant chronic hepatitis C. Three group participant study ; 1 ) elevate alanine transaminase ( ALT ) level , 2 ) normal ALT level , 3 ) human immunodeficiency virus ( HIV ) co-infection . Participants genotype 1 , 4 , 5 6 receive peginterferon alfa-2a 180 microgram ( mcg ) subcutaneous ( SC ) weekly ( qw ) + ribavirin 1000-1200 milligram ( mg ) orally ( PO ) daily ( dependent body weight ) 48 week , genotype 2 3 receive peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily 24 week , participant HIV co-infection receive peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily 48 week . The anticipated time study treatment 48 week , target sample size 300 individual .</brief_summary>
	<brief_title>A Study Combination Treatment With Peginterferon Alfa-2a ( Pegasys ) Plus Ribavirin ( Copegus ) Participants With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult participant , great equal ( &gt; = ) 18 year age Chronic hepatitis C , detectable serum hepatitie C virus ( HCV ) ribonucleic acid ( RNA ) Scheduled treatment peginterferon alfa2a Compensated liver disease Women fertile age must inform obligation use adequate contraception 6 month post treatment ribavirin ( Copegus® ) Men sexual partner fertile age must inform obligatory contraception prevent pregnancy course treatment ribavirin ( Copegus® ) well 6 month treatment cessation Female participant study must negative pregnancy test perform sooner within 2 week precede plan inclusion study Men sexual partner fertile age must produce negative result partner 's pregnancy test perform sooner within 2 week precede plan partner 's inclusion study Chronic liver disease chronic hepatitis C Active hepatitis A virus hepatitis B virus infection Therapy systemic antiviral , antineoplastic immunomodulatory treatment less equal ( &lt; = ) 6 month prior first dose study drug Hemoglobin &lt; 120 gram per liter ( g/L ) female subject &lt; 130 g/L male subject ( result must older 2 week prior inclusion study ) The platelet count &lt; 90 x 10^9/liter ( result must older 2 week prior inclusion study Neutrofils count &lt; 1.5 x 10^9/liter ( result must older 2 week prior inclusion study ) Subjects increase risk anaemia , subject , risk serious health problem result anaemia decrease hemoglobin ( e.g. , subject serious cardiovascular cerebrovascular disease ) History presence serious mental disease , especially depression , , accord investigator 's opinion , allow administration peginterferon alfa2a ( Pegasys® ) History presence disease consequent immunodeficiency ( e.g. , inflammatory disease intestine , idiopathic thrombocytopenic purpura , systemic lupus erythematodes , rheumatoid arthritis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>